In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited¹, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice², and medicinal cannabis use is poorly documented in electronic medical records (EMRs)³. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use⁴.

With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased⁵. Products vary in chemical composition⁶, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.

在美国，有超过 550 万注册患者参加国家监管的药用大麻计划，许多人使用大麻产品（来自含有 <0.3% delta-9-四氢大麻酚 （THC） 的大麻）用于治疗目的。然而，对非药用大麻产品的临床研究仍然有限¹，医疗保健提供者认为在将药用大麻纳入其实践方面没有接受过足够的培训²，而且药用大麻的使用在电子病历 （EMR） 中的记录很差 ³。这些问题凸显了对药用大麻使用影响的患者层面数据的需求⁴。

随着美国一些州的大麻零售合法化，消费者可获得的大麻产品的多样性大大增加⁵。产品在化学成分⁶、剂量和预期给药途径方面各不相同，所有这些都会影响临床效果、安全性和滥用易感性，应在临床决策中加以考虑。大麻产品的多样性和定义不明确的命名法导致难以评估药用大麻对健康的影响。